Gene chip analysis revealed that high CD68/CD8 ratio is also a predictive biomarker for reduced rate of pCR in 311 breast cancer patients from a Swedish cohort that underwent neoadjuvant chemotherapy (PTX and fluorouracil-doxorubicin-cyclophosphamide) (72). The gene discussed is CD68; the disease is breast carcinoma.